Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Shattuck Labs, Inc. - Common Stock (NQ: STTK )

1.470 +0.070 (+5.00%)
Streaming Delayed Price Updated: 10:37 AM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 123,819
Open 1.360
Bid (Size) 1.450 (14)
Ask (Size) 1.470 (4)
Prev. Close 1.400
Today's Range 1.360 - 1.478
52wk Range 1.070 - 11.76
Shares Outstanding 42,122,778
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga

Performance

YTD
-80.56%
-80.56%
1 Month
-59.62%
-59.62%
3 Month
-60.27%
-60.27%
6 Month
-84.94%
-84.94%
1 Year
-8.13%
-8.13%

More News

Read More
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Via NewMediaWire
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Via TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
Via NewMediaWire
Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Assessing Shattuck Labs: Insights From 7 Financial Analysts
Via Benzinga
Assessing Shattuck Labs: Insights From 6 Financial Analysts
Via Benzinga
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
Via TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
Via NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
Via TheNewswire.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
From Shattuck Labs, Inc.
Via GlobeNewswire
STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
From Shattuck Labs, Inc.
Via GlobeNewswire
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
From Shattuck Labs, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.